Pharma Journalist -

Vir Biotechnology, Inc. announced that it has signed a letter of intent with Biogen Inc. (Nasdaq: BIIB) for the development and clinical manufacturing of human monoclonal antibodies for…
Read More...

Emergent BioSolutions Inc. announced that it has initiated development of two product candidates for the treatment and prevention of coronavirus disease (COVID-19). These product…
Read More...

NICE has today (12 March 2020) published final draft guidance which recommends fremanezumab (also called Ajovy and made by Teva Pharmaceuticals) for preventing chronic migraine. The…
Read More...

Harbour BioMed (HBM) announced successful completion of its Series B+ round financing of $75 million to accelerate the advancement of its clinical-stage compounds and growing portfolio…
Read More...

Kuur Therapeutics announced the launch of its new business in partnership with Baylor College of Medicine and Baylor’s Center for Cell and Gene Therapy. Houston-based Kuur Therapeutics…
Read More...

Bristol Myers Squibb Company announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug…
Read More...

WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs) for cancer immunotherapy, and Cognate BioServices, Inc., a leading contract development…
Read More...

Chime Biologics announced operations as an independent and stand-alone Biologics CDMO company. With the separation from JHL Biotech complete, Chime Biologics is now focused on…
Read More...

InMed Pharmaceuticals Inc. reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV). INM-755 is a CBN cream intended as a…
Read More...

Phio Pharmaceuticals Corp. a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic…
Read More...